Tula, Tula, Russian Federation
Tula, Tula, Russian Federation
Osvescheny osnovnye voprosy, svyazannye s gipertroficheskoy kardiomiopatiey. Nesmotrya na neshirokuyu rasprostranennost', dannaya patologiya ostaetsya odnoy iz samyh chastyh prichin vnezapnoy serdechnoy smerti u molodyh lyudey. Predstavlena informaciya po diagnostike i lecheniyu bol'nyh s gipertroficheskoy kardiomiopatiey (razlichnyh patofiziologicheskih variantov).
gipertroficheskaya kardiomiopatiya, etiologiya, patofiziologiya, lechenie.
1. Gipertroficheskaya kardiomiopatiya: formy i varianty techeniya, podhody k medikamentoznoy terapii/Yu.N. Belenkov, E.V. Privalova, V.Yu. Kaplunova, I.S. Chekneva,G.A. Schakar'yanc, M.V. Kozhevnikova//EFFEKTIVNAYa FARMAKOTERAPIYa. Endokrinologiya.- 2016.-№2 (28)
2. Gipertroficheskaya kardiomiopatiya: geneticheskie izmeneniya, patogenez i patofiziologiya/ N.T.Vatutin, G.G.Taradin, M.S.Maron// Rossiyskiy kardiologicheskiy zhurnal.-2014.-№5(109).-S.35-42
3. Renin-angiotenzin-al'dosteronovaya sistema pri gipertroficheskoy kardiomiopatii/ M.V. Kozhevnikova, V.Yu. Kaplunova, E.V. Privalova, N.V. Habarova, Yu.N. Belenkov// Kardiologiya.-2014.-№3.-S.23-28
4. Endokrinnye zabolevaniya//Moiseev V.S. Kardiomiopatii i miokardity/ V.S.Moiseev, G.K. Kiyakbaev.-M.,2013.- S.274-288.
5. Matriksnye metalloproteinazy i gipertroficheskaya kardiomiopatiya/ E.V.Privalova, V.Yu. Kaplunova, M.V. Kozhevnikova, N.V. Habarova, G.A.Shakar'yanc, Yu.N.Belenkov// Kardiologiya.- 2014.-№5.- S. 4-7
6. Bonow R.O. Left ventricular diastolic function in hypertrophic cardiomyopathy // Herz. 1991. Vol. 16. № 1. P. 13-21.
7. Cecchi F., Olivotto I., Nistri S. et al. Midventricular obstruction and clinical decision-making in obstructive hypertrophic cardiomyopathy // Herz. 2006. Vol. 31. № 9. P. 871-876.
8. Dimitrow P.P., Krzanowski M., Nizankowski R. et al. Comparison of the effect of verapamil and propranolol on response of coronary vasomotion to cold pressor test in symptomatic patients with hypertrophic cardiomyopathy // Cardiovasc. Drugs Ther. 2000. Vol. 14. № 6. P. 643-650.
9. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J.Amer.Coll. Cardiol.2011;58 (25);2703-38.
10. De Gregorio C. Refined echocardiographic assessment and contemporary medical treatment of obstructive hypertrophic cardiomyopathy // Cardiovasc. Hematol. Disord. Drug Targets. 2007. Vol. 7. № 3. P. 174-187.
11. MacDonald K.A., Kittleson M.D., Larson R.F. et al. The effect of ramipril on left ventricular mass, myocardial fibrosis, diastolic function, and plasma neurohormones in Maine Coon cats with familial hypertrophic cardiomyopathy without heart failure // J. Vet. Intern. Med. 2006. Vol. 20. № 5. P. 1093-1105.
12. Maron B.J. Hypertrophic cardiomyopathy: a systematic review // JAMA. 2002. Vol. 287. № 10. P. 1308-1320.
13. Maron M.S., Olivotto I., Betocchi S. et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy // N. Engl. J. Med. 2003. Vol. 348. № 4. P. 295-303.
14. De Resende M.M., Kriegel A.J., Greene A.S. Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy // J. Cardiovasc. Pharmacol. 2006. Vol. 48. № 6. P. 265-273.
15. Schlepper M. Identification of patients with atrial fibrillation at risk for thromboembolism // Atrial Fibrillation. Mechanisms and Therapeutic Strategies / eds. S.B. Olsson, M.A. Allessie, R.W.F. Campbell. 1994. P. 15-24.
16. Singh B.N. An overview of slow channel blocking drugs: pharmacological basis for therapeutic applications // Cardiology. 1982. Vol. 69. Suppl. P. 2-25.
17. Spirito P., Autore C. Management of hypertrophic cardiomyopathy // BMJ. 2006. Vol. 332. № 7552. P. 1251-1255.
18. Wigle E.D., Rakowski H., Kimball B.P., Williams W.G. Hypertrophic cardiomyopathy. Clinical spectrum and treatment // Circulation. 1995. Vol. 92. № 7. P. 1680-1692.
